Capricor Therapeutics
Business Services · California, United States · 201-500 Employees
View Company Info for Free
Overview
Headquarters
10865 Road to the Cure Ste 150, San Dieg...Phone Number
(858) 727-1755Website
www.capricor.comRevenue
$11.1 MillionStock Symbol
CAPRIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Capricor Therapeutics
Capricor Therapeutics is a biotechnology company focused on developing innovative therapies designed to make a meaningful impact on patients’ lives. The company specializes in biologics, with a primary focus on cell- and exosome-based technologies for the treatment and prevention of a broad range of diseases. Capricor aims to advance transformative therapeutic approaches by leveraging its expertise in regenerative medicine, cellular therapies, and exosome technology to address significant unmet medical needs.Explore more
Capricor Therapeutics Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Capricor Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Capricor Therapeutics launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Capricor Therapeutics had a recent Job posting/layoffs
Earning: See what the market has to say on Capricor Therapeutics recently announced quarterly report
Check if Capricor Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Check out if Capricor Therapeutics is spiking on competitors!
Website visits: Recent activity has been detected on your website
Capricor Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Capricor Therapeutics has new funding data
Congratulate Masked Content for being promoted to Masked Content at Capricor Therapeutics
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Capricor Therapeutics
Compare insights from companies similar to Capricor Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$196.1M
201-500
Public
$466M
1990
Bryan RidgellSenior Vice President, Portfolio and Project Management, and Chief of Staff
Company Profile Activity
Activity Insights
Capricor Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Capricor Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Capricor Therapeutics.
Capricor Therapeutics financials insights
Gather financial insights about Capricor Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Debt
$150K
2024
Private Equity
$35M
Capricor Therapeutics Tech Stack
A closer look at the technologies used by Capricor Therapeutics
See more technologies
Most Recent Scoops
Facilities Relocation / Expansion
Facilities Relocation/Expansion, Leasing, Manufacturing Operations
Person-Based
Stake & Stock Ownership, Finance
Open Position
Open Position
Open Position
Capricor Therapeutics News & Media
CLASS ACTION NOTICE: Berger Montague Advises Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors to Inquire About a Securities Fraud Class Action
PHILADELPHIA, Aug. 24, 2026 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announces a class action lawsuit against Capricor Therapeutics, Inc. (NASDAQ: CAPR) ("Capricor" or the "Company") on behalf of investors who purchased or acquired Capricor securities during the...Capricor Therapeutics Announces Extension of PDUFA Target Action Date as FDA Continues Review of Deramiocel BLA
– New PDUFA target action date of November 22, 2026 follows submission of additional Phase 3 HOPE-3 data and analyses supporting a refined proposed indication –Investor Reminder: Capricor Therapeutics (NASDAQ:CAPR) Investors are Encouraged to Contact BFA Law – Securities Fraud Lawsuit Pending Over Mine Production Issues
Capricor Therapeutics (NASDAQ:CAPR) Investors are Encouraged to Contact BFA Law – Securities Fraud Lawsuit Pending Over Mine Production IssuesBronstein, Gewirtz & Grossman LLC Urges Capricor Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
New class action for Capricor (CAPR) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 9/28/2026
Read more news
Top Business Services Companies
See more top companies
Frequently Asked Questions Regarding Capricor Therapeutics
Sign Up For FreeTo access detailed company insights
Capricor Therapeutics is a biotechnology company focused on developing innovative therapies designed to make a meaningful impact on patients’ lives. The company specializes in biologics, with a primary focus on cell- and exosome-based technologies for the treatment and prevention of a broad range of diseases. Capricor aims to advance transformative... Read More
